Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
Rick. Ferenc G FG; Szalontay. Luca L; Schally. Andrew V AV; Block. Norman L NL; Nadji. Mehrdad M; Szepeshazi. Karoly K; Vidaurre. Irving I; Zarandi. Marta M; Kovacs. Magdolna M; Rekasi. Zoltan Z
Key Findings
- GHRH antagonist JMR‑132 plus LHRH antagonist cetrorelix reduced prostate weight by 30% in rats (p<0.01).
- The combo lowered prostate‑specific antigen, inflammatory cytokines (IL‑1β), NF‑κB, COX‑2 and other prostate markers.
- Both hormones appear to act through their own receptors in the prostate, suggesting a direct inhibitory effect.
Practical Outcomes
- These results point to a potential new treatment for benign prostatic hyperplasia, but they involve hormone antagonists—not sermorelin or other supplements. For biohackers, there’s no actionable protocol to adopt, and trying to block GHRH could counteract the intended benefits of sermorelin.
Summary
In rats with hormone‑induced enlarged prostates, giving a drug that blocks growth‑hormone‑releasing hormone (GHRH) together with a drug that blocks luteinizing‑hormone‑releasing hormone (LHRH) cut prostate size by about 30% and lowered several prostate‑related blood markers.
Abstract
Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate volume and an increased urinary peak flow rate in men with benign prostatic hyperplasia. We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. We evaluated the effects of the growth hormone-releasing hormone antagonist JMR-132, given at a dose of 40 μg daily, the luteinizing hormone-releasing hormone antagonist cetrorelix, given at a dose of 0.625 mg/kg, and their combination on testosterone induced benign prostatic hyperplasia in adult male Wistar rats in vivo. Prostate tissue was examined biochemically and histologically. Serum levels of growth hormone, luteinizing hormone, insulin-like growth factor-1, dihydrotestosterone and prostate specific antigen were determined. Marked shrinkage of the rat prostate (30.3%) occurred in response to the combination of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists (p<0.01). The combination strongly decreased prostatic prostate specific antigen, 6-transmembrane epithelial antigen of the prostate, interleukin-1β, nuclear factor-κβ and cyclooxygenase-2, and decreased serum prostate specific antigen. A combination of growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist potentiated a reduction in prostate weight in an experimental benign prostatic hyperplasia model. Results suggest that this shrinkage in prostate volume was induced by the direct inhibitory effects of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists exerted through their respective prostatic receptors. These findings suggest that growth hormone-releasing hormone antagonists and/or their combination with luteinizing hormone-releasing hormone antagonists should be considered for further development as therapy for benign prostatic hyperplasia.
Study Information
pubmed
2012
2012-02-17T00:00:00.000Z
10.1016/j.juro.2011.11.081
37
31